LUXLung5_1A | R Documentation |
Kaplan-Meier digitized data from LUXLung5, figure 1A (PMID 26646759). A reported sample size of 220 for a primary endpoint of PFS in lung cancer.
LUXLung5_1A
A data frame of 202 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (afatinib_paclitaxel, chemo) | |
Schuler M, Yang JC-H, Park K, et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 2016; 27: 417–23.
summary(LUXLung5_1A)
kmplot(LUXLung5_1A)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.